PhaseBio Pharmaceuticals, Inc.
Use of modified vasoactive intestinal peptides in the treatment of hypertension

Abstract:

The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided.